Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses.

Bouillier C, Rincheval V, Sitterlin D, Blouquit-Laye S, Desquesnes A, Eléouët JF, Gault E, Rameix-Welti MA.

J Vis Exp. 2019 Apr 4;(146). doi: 10.3791/59218.

PMID:
31009004
2.

Evaluation of the Antiviral Activity of Sephin1 Treatment and Its Consequences on eIF2α Phosphorylation in Response to Viral Infections.

Fusade-Boyer M, Dupré G, Bessière P, Khiar S, Quentin-Froignant C, Beck C, Lecollinet S, Rameix-Welti MA, Eléouët JF, Tangy F, Lajoie B, Bertagnoli S, Vidalain PO, Gallardo F, Volmer R.

Front Immunol. 2019 Feb 12;10:134. doi: 10.3389/fimmu.2019.00134. eCollection 2019.

3.

Boosting subdominant neutralizing antibody responses with a computationally designed epitope-focused immunogen.

Sesterhenn F, Galloux M, Vollers SS, Csepregi L, Yang C, Descamps D, Bonet J, Friedensohn S, Gainza P, Corthésy P, Chen M, Rosset S, Rameix-Welti MA, Éléouët JF, Reddy ST, Graham BS, Riffault S, Correia BE.

PLoS Biol. 2019 Feb 21;17(2):e3000164. doi: 10.1371/journal.pbio.3000164. eCollection 2019 Feb.

4.

Biochemical characterization of the respiratory syncytial virus N0-P complex in solution.

Esneau C, Raynal B, Roblin P, Brûlé S, Richard CA, Fix J, Eléouët JF, Galloux M.

J Biol Chem. 2019 Mar 8;294(10):3647-3660. doi: 10.1074/jbc.RA118.006453. Epub 2019 Jan 9.

PMID:
30626736
5.

Does Intrinsic Disorder in Proteins Favor Their Interaction with Lipids?

Deryusheva E, Nemashkalova E, Galloux M, Richard CA, Eléouët JF, Kovacs D, Van Belle K, Tompa P, Uversky V, Permyakov S.

Proteomics. 2019 Mar;19(6):e1800098. doi: 10.1002/pmic.201800098. Epub 2019 Jan 25.

PMID:
30592560
6.

First demonstration of the circulation of a pneumovirus in French pigs by detection of anti-swine orthopneumovirus nucleoprotein antibodies.

Richard CA, Hervet C, Ménard D, Gutsche I, Normand V, Renois F, Meurens F, Eléouët JF.

Vet Res. 2018 Dec 5;49(1):118. doi: 10.1186/s13567-018-0615-x.

7.

The Structure of the Human Respiratory Syncytial Virus M2-1 Protein Bound to the Interaction Domain of the Phosphoprotein P Defines the Orientation of the Complex.

Selvaraj M, Yegambaram K, Todd EJAA, Richard CA, Dods RL, Pangratiou GM, Trinh CH, Moul SL, Murphy JC, Mankouri J, Éléouët JF, Barr JN, Edwards TA.

MBio. 2018 Nov 13;9(6). pii: e01554-18. doi: 10.1128/mBio.01554-18.

8.

RSV hijacks cellular protein phosphatase 1 to regulate M2-1 phosphorylation and viral transcription.

Richard CA, Rincheval V, Lassoued S, Fix J, Cardone C, Esneau C, Nekhai S, Galloux M, Rameix-Welti MA, Sizun C, Eléouët JF.

PLoS Pathog. 2018 Feb 28;14(3):e1006920. doi: 10.1371/journal.ppat.1006920. eCollection 2018 Mar.

9.

Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism.

Cagno V, Andreozzi P, D'Alicarnasso M, Jacob Silva P, Mueller M, Galloux M, Le Goffic R, Jones ST, Vallino M, Hodek J, Weber J, Sen S, Janeček ER, Bekdemir A, Sanavio B, Martinelli C, Donalisio M, Rameix Welti MA, Eleouet JF, Han Y, Kaiser L, Vukovic L, Tapparel C, Král P, Krol S, Lembo D, Stellacci F.

Nat Mater. 2018 Feb;17(2):195-203. doi: 10.1038/nmat5053. Epub 2017 Dec 18.

PMID:
29251725
10.

Modular cell-based platform for high throughput identification of compounds that inhibit a viral interferon antagonist of choice.

Vasou A, Paulus C, Narloch J, Gage ZO, Rameix-Welti MA, Eléouët JF, Nevels M, Randall RE, Adamson CS.

Antiviral Res. 2018 Feb;150:79-92. doi: 10.1016/j.antiviral.2017.10.012. Epub 2017 Oct 14.

11.

Functional organization of cytoplasmic inclusion bodies in cells infected by respiratory syncytial virus.

Rincheval V, Lelek M, Gault E, Bouillier C, Sitterlin D, Blouquit-Laye S, Galloux M, Zimmer C, Eleouet JF, Rameix-Welti MA.

Nat Commun. 2017 Sep 15;8(1):563. doi: 10.1038/s41467-017-00655-9.

12.

Respiratory Syncytial Virus Infects Regulatory B Cells in Human Neonates via Chemokine Receptor CX3CR1 and Promotes Lung Disease Severity.

Zhivaki D, Lemoine S, Lim A, Morva A, Vidalain PO, Schandene L, Casartelli N, Rameix-Welti MA, Hervé PL, Dériaud E, Beitz B, Ripaux-Lefevre M, Miatello J, Lemercier B, Lorin V, Descamps D, Fix J, Eléouët JF, Riffault S, Schwartz O, Porcheray F, Mascart F, Mouquet H, Zhang X, Tissières P, Lo-Man R.

Immunity. 2017 Feb 21;46(2):301-314. doi: 10.1016/j.immuni.2017.01.010.

13.

A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.

Gaillard V, Galloux M, Garcin D, Eléouët JF, Le Goffic R, Larcher T, Rameix-Welti MA, Boukadiri A, Héritier J, Segura JM, Baechler E, Arrell M, Mottet-Osman G, Nyanguile O.

Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e02241-16. doi: 10.1128/AAC.02241-16. Print 2017 Apr.

14.

New Insights into Structural Disorder in Human Respiratory Syncytial Virus Phosphoprotein and Implications for Binding of Protein Partners.

Pereira N, Cardone C, Lassoued S, Galloux M, Fix J, Assrir N, Lescop E, Bontems F, Eléouët JF, Sizun C.

J Biol Chem. 2017 Feb 10;292(6):2120-2131. doi: 10.1074/jbc.M116.765958. Epub 2016 Dec 28.

15.

Non-invasive epicutaneous vaccine against Respiratory Syncytial Virus: Preclinical proof of concept.

Hervé PL, Descamps D, Deloizy C, Dhelft V, Laubreton D, Bouguyon E, Boukadiri A, Dubuquoy C, Larcher T, Benhamou PH, Eléouët JF, Bertho N, Mondoulet L, Riffault S.

J Control Release. 2016 Dec 10;243:146-159. doi: 10.1016/j.jconrel.2016.10.003. Epub 2016 Oct 6.

16.

RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine.

Hervé PL, Deloizy C, Descamps D, Rameix-Welti MA, Fix J, McLellan JS, Eléouët JF, Riffault S.

Nanomedicine. 2017 Feb;13(2):411-420. doi: 10.1016/j.nano.2016.08.006. Epub 2016 Aug 20.

17.

Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication.

Bailly B, Richard CA, Sharma G, Wang L, Johansen L, Cao J, Pendharkar V, Sharma DC, Galloux M, Wang Y, Cui R, Zou G, Guillon P, von Itzstein M, Eléouët JF, Altmeyer R.

Sci Rep. 2016 May 19;6:25806. doi: 10.1038/srep25806.

18.

A Druggable Pocket at the Nucleocapsid/Phosphoprotein Interaction Site of Human Respiratory Syncytial Virus.

Ouizougun-Oubari M, Pereira N, Tarus B, Galloux M, Lassoued S, Fix J, Tortorici MA, Hoos S, Baron B, England P, Desmaële D, Couvreur P, Bontems F, Rey FA, Eléouët JF, Sizun C, Slama-Schwok A, Duquerroy S.

J Virol. 2015 Nov;89(21):11129-43. doi: 10.1128/JVI.01612-15. Epub 2015 Aug 5.

19.

A bovine respiratory syncytial virus model with high clinical expression in calves with specific passive immunity.

Blodörn K, Hägglund S, Gavier-Widen D, Eléouët JF, Riffault S, Pringle J, Taylor G, Valarcher JF.

BMC Vet Res. 2015 Mar 25;11:76. doi: 10.1186/s12917-015-0389-6.

20.

Fine mapping and characterization of the L-polymerase-binding domain of the respiratory syncytial virus phosphoprotein.

Sourimant J, Rameix-Welti MA, Gaillard AL, Chevret D, Galloux M, Gault E, Eléouët JF.

J Virol. 2015 Apr;89(8):4421-33. doi: 10.1128/JVI.03619-14. Epub 2015 Feb 4.

21.

Identification and characterization of the binding site of the respiratory syncytial virus phosphoprotein to RNA-free nucleoprotein.

Galloux M, Gabiane G, Sourimant J, Richard CA, England P, Moudjou M, Aumont-Nicaise M, Fix J, Rameix-Welti MA, Eléouët JF.

J Virol. 2015 Apr;89(7):3484-96. doi: 10.1128/JVI.03666-14. Epub 2015 Jan 7.

22.

Interactome analysis of the human respiratory syncytial virus RNA polymerase complex identifies protein chaperones as important cofactors that promote L-protein stability and RNA synthesis.

Munday DC, Wu W, Smith N, Fix J, Noton SL, Galloux M, Touzelet O, Armstrong SD, Dawson JM, Aljabr W, Easton AJ, Rameix-Welti MA, de Oliveira AP, Simabuco FM, Ventura AM, Hughes DJ, Barr JN, Fearns R, Digard P, Eléouët JF, Hiscox JA.

J Virol. 2015 Jan 15;89(2):917-30. doi: 10.1128/JVI.01783-14. Epub 2014 Oct 29.

23.

Visualizing the replication of respiratory syncytial virus in cells and in living mice.

Rameix-Welti MA, Le Goffic R, Hervé PL, Sourimant J, Rémot A, Riffault S, Yu Q, Galloux M, Gault E, Eléouët JF.

Nat Commun. 2014 Oct 3;5:5104. doi: 10.1038/ncomms6104.

PMID:
25277263
24.

Vaccine safety and efficacy evaluation of a recombinant bovine respiratory syncytial virus (BRSV) with deletion of the SH gene and subunit vaccines based on recombinant human RSV proteins: N-nanorings, P and M2-1, in calves with maternal antibodies.

Blodörn K, Hägglund S, Fix J, Dubuquoy C, Makabi-Panzu B, Thom M, Karlsson P, Roque JL, Karlstam E, Pringle J, Eléouët JF, Riffault S, Taylor G, Valarcher JF.

PLoS One. 2014 Jun 19;9(6):e100392. doi: 10.1371/journal.pone.0100392. eCollection 2014.

25.

Characterization of an experimental vaccine for bovine respiratory syncytial virus.

Hägglund S, Hu K, Blodörn K, Makabi-Panzu B, Gaillard AL, Ellencrona K, Chevret D, Hellman L, Bengtsson KL, Riffault S, Taylor G, Valarcher JF, Eléouët JF.

Clin Vaccine Immunol. 2014 Jul;21(7):997-1004. doi: 10.1128/CVI.00162-14. Epub 2014 May 14.

26.

Crystal structure of the essential transcription antiterminator M2-1 protein of human respiratory syncytial virus and implications of its phosphorylation.

Tanner SJ, Ariza A, Richard CA, Kyle HF, Dods RL, Blondot ML, Wu W, Trincão J, Trinh CH, Hiscox JA, Carroll MW, Silman NJ, Eléouët JF, Edwards TA, Barr JN.

Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1580-5. doi: 10.1073/pnas.1317262111. Epub 2014 Jan 13.

27.

A novel subnucleocapsid nanoplatform for mucosal vaccination against influenza virus that targets the ectodomain of matrix protein 2.

Hervé PL, Raliou M, Bourdieu C, Dubuquoy C, Petit-Camurdan A, Bertho N, Eléouët JF, Chevalier C, Riffault S.

J Virol. 2014 Jan;88(1):325-38. doi: 10.1128/JVI.01141-13. Epub 2013 Oct 23.

28.

The respiratory syncytial virus nucleoprotein-RNA complex forms a left-handed helical nucleocapsid.

Bakker SE, Duquerroy S, Galloux M, Loney C, Conner E, Eléouët JF, Rey FA, Bhella D.

J Gen Virol. 2013 Aug;94(Pt 8):1734-8. doi: 10.1099/vir.0.053025-0. Epub 2013 May 15.

29.

Epidemiology, molecular virology and diagnostics of Schmallenberg virus, an emerging orthobunyavirus in Europe.

Doceul V, Lara E, Sailleau C, Belbis G, Richardson J, Bréard E, Viarouge C, Dominguez M, Hendrikx P, Calavas D, Desprat A, Languille J, Comtet L, Pourquier P, Eléouët JF, Delmas B, Marianneau P, Vitour D, Zientara S.

Vet Res. 2013 May 15;44:31. doi: 10.1186/1297-9716-44-31. Review.

30.

Structure and functional analysis of the RNA- and viral phosphoprotein-binding domain of respiratory syncytial virus M2-1 protein.

Blondot ML, Dubosclard V, Fix J, Lassoued S, Aumont-Nicaise M, Bontems F, Eléouët JF, Sizun C.

PLoS Pathog. 2012;8(5):e1002734. doi: 10.1371/journal.ppat.1002734. Epub 2012 May 31.

31.

Nucleoprotein nanostructures combined with adjuvants adapted to the neonatal immune context: a candidate mucosal RSV vaccine.

Remot A, Roux X, Dubuquoy C, Fix J, Bouet S, Moudjou M, Eléouët JF, Riffault S, Petit-Camurdan A.

PLoS One. 2012;7(5):e37722. doi: 10.1371/journal.pone.0037722. Epub 2012 May 24.

32.

Characterization of a viral phosphoprotein binding site on the surface of the respiratory syncytial nucleoprotein.

Galloux M, Tarus B, Blazevic I, Fix J, Duquerroy S, Eléouët JF.

J Virol. 2012 Aug;86(16):8375-87. doi: 10.1128/JVI.00058-12. Epub 2012 May 23.

33.
34.

1H, 13C, and 15N resonance assignment of the central domain of hRSV transcription antitermination factor M2-1.

Dubosclard V, Blondot ML, Eléouët JF, Bontems F, Sizun C.

Biomol NMR Assign. 2011 Oct;5(2):237-9. doi: 10.1007/s12104-011-9308-3. Epub 2011 Apr 27.

PMID:
21523439
35.

A new subunit vaccine based on nucleoprotein nanoparticles confers partial clinical and virological protection in calves against bovine respiratory syncytial virus.

Riffault S, Meyer G, Deplanche M, Dubuquoy C, Durand G, Soulestin M, Castagné N, Bernard J, Bernardet P, Dubosclard V, Bernex F, Petit-Camurdan A, Deville S, Schwartz-Cornil I, Eléouët JF.

Vaccine. 2010 May 7;28(21):3722-34. doi: 10.1016/j.vaccine.2010.03.008. Epub 2010 Mar 20.

PMID:
20307593
36.

Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus.

Tawar RG, Duquerroy S, Vonrhein C, Varela PF, Damier-Piolle L, Castagné N, MacLellan K, Bedouelle H, Bricogne G, Bhella D, Eléouët JF, Rey FA.

Science. 2009 Nov 27;326(5957):1279-83. doi: 10.1126/science.1177634.

37.

The respiratory syncytial virus M2-1 protein forms tetramers and interacts with RNA and P in a competitive manner.

Tran TL, Castagné N, Dubosclard V, Noinville S, Koch E, Moudjou M, Henry C, Bernard J, Yeo RP, Eléouët JF.

J Virol. 2009 Jul;83(13):6363-74. doi: 10.1128/JVI.00335-09. Epub 2009 Apr 22.

38.

Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus.

Roux X, Dubuquoy C, Durand G, Tran-Tolla TL, Castagné N, Bernard J, Petit-Camurdan A, Eléouët JF, Riffault S.

PLoS One. 2008 Mar 12;3(3):e1766. doi: 10.1371/journal.pone.0001766.

39.

The nine C-terminal amino acids of the respiratory syncytial virus protein P are necessary and sufficient for binding to ribonucleoprotein complexes in which six ribonucleotides are contacted per N protein protomer.

Tran TL, Castagné N, Bhella D, Varela PF, Bernard J, Chilmonczyk S, Berkenkamp S, Benhamo V, Grznarova K, Grosclaude J, Nespoulos C, Rey FA, Eléouët JF.

J Gen Virol. 2007 Jan;88(Pt 1):196-206.

PMID:
17170452
40.

Replication of bovine respiratory syncytial virus in murine cells depends on type I interferon-receptor functionality.

Riffault S, Dubuquoy C, Castagné N, Baranowski E, Charley B, Eléouët JF.

J Gen Virol. 2006 Aug;87(Pt 8):2145-8.

PMID:
16847109
41.

Biochemical characterization of the respiratory syncytial virus P-P and P-N protein complexes and localization of the P protein oligomerization domain.

Castagné N, Barbier A, Bernard J, Rezaei H, Huet JC, Henry C, Da Costa B, Eléouët JF.

J Gen Virol. 2004 Jun;85(Pt 6):1643-53.

PMID:
15166449
42.

Comparative study of in-situ cell death induced by the viruses of viral haemorrhagic septicaemia (VHS) and infectious pancreatic necrosis (IPN) in rainbow trout.

Eléouët JF, Druesne N, Chilmonczyk S, Monge D, Dorson M, Delmas B.

J Comp Pathol. 2001 May;124(4):300-7.

PMID:
11437506
43.

The viral nucleocapsid protein of transmissible gastroenteritis coronavirus (TGEV) is cleaved by caspase-6 and -7 during TGEV-induced apoptosis.

Eléouët JF, Slee EA, Saurini F, Castagné N, Poncet D, Garrido C, Solary E, Martin SJ.

J Virol. 2000 May;74(9):3975-83.

44.
45.

Complete sequence (20 kilobases) of the polyprotein-encoding gene 1 of transmissible gastroenteritis virus.

Eleouet JF, Rasschaert D, Lambert P, Levy L, Vende P, Laude H.

Virology. 1995 Feb 1;206(2):817-22.

46.

Complete genomic sequence of the transmissible gastroenteritis virus.

Eleouet JF, Rasschaert D, Lambert P, Levy L, Vende P, Laude H.

Adv Exp Med Biol. 1995;380:459-61. No abstract available.

PMID:
8830524
47.

Transcriptional regulation of the pyruvate kinase erythroid-specific promoter.

Max-Audit I, Eleouet JF, Roméo PH.

J Biol Chem. 1993 Mar 15;268(8):5431-7.

49.

A T-cell specific TCR delta DNA binding protein is a member of the human GATA family.

Joulin V, Bories D, Eléouet JF, Labastie MC, Chrétien S, Mattéi MG, Roméo PH.

EMBO J. 1991 Jul;10(7):1809-16.

Supplemental Content

Loading ...
Support Center